The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix

Clinical Cancer Research

Volumn 9, Issue 8, 2003, Pages 2981-2984

  Cohen, Yoram ^a   Singer, Gad ^b   Lavie, Ofer ^c   Dong, Seung Myung ^a   Beller, Uziel ^d   Sidransky, David ^a,e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UNIVERSITY OF BASEL   (Switzerland)

^c CARMEL MEDICAL CENTER   (Israel)

^d BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN PAPILLOMAVIRUS E6 PROTEIN; HUMAN PAPILLOMAVIRUS E7 PROTEIN; PROTEIN P53; RAS ASSOCIATION DOMAIN FAMILY 1A PROTEIN; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADENOCARCINOMA; ARTICLE; CARCINOGENESIS; CHROMOSOME 3; CHROMOSOME LOSS; CONTROLLED STUDY; GENE INACTIVATION; GENE SILENCING; HUMAN; HUMAN TISSUE; MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RASSF1A GENE; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA; VIRUS INFECTION; WART VIRUS;

ADENOCARCINOMA; ALLELES; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DNA METHYLATION; FEMALE; GENE SILENCING; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SULFITES; TUMOR SUPPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 0043026893     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Pisani, P., Parkin, D. M., Bray, F., and Ferlay, J. Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer, 83: 18-29, 1999.
2. Bosch, F. X., Manos, M. M., Munoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Moreno, V., Kurman, R., and Shah, K. V. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J. Natl. Cancer Inst. (Bethesda), 87: 796-802, 1995.
3. Sanclemente, G., and Gill, D. K. Human papillomavirus molecular biology and pathogenesis. J. Eur. Acad. Dermatol. Venereol., 16: 231-240, 2002.
4. Ferenczy, A., and Franco, E. Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol., 3: 11-16, 2002.
5. Boyer, S. N., Wazer, D. E., and Band, V. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res., 56: 4620-4624, 1996.
6. Baylin, S. B., Herman, J. G., Graff, J. R., Vertino, P. M., and Issa, J. P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv. Cancer Res., 72: 141-196, 1998.
7. Jones, P. A., and Laird, P. W. Cancer epigenetics comes of age. Nat. Genet., 21: 163-167, 1999.
8. Baylin, S. B., Esteller, M., Rountree, M. R., Bachman, K. E., Schuebel, K., and Herman, J. G. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet., 10: 687-692, 2001.
9. Esteller, M., and Herman, J. G. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J. Pathol., 196: 1-7, 2002.
10. Acevedo, C. M., Henriquez, M., Emmert-Buck, M. R., and Chuaqui, R. F. Loss of heterozygosity on chromosome arms 3p and 6q in microdissected adenocarcinomas of the uterine cervix and adenocarcinoma in situ. Cancer (Phila.), 94: 793-802, 2002.
11. Kok, K., Naylor, S. L., and Buys, C. H. Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes. Adv. Cancer Res., 71: 27-92, 1997.
12. Dammann, R., Li, C., Yoon, J. H., Chin, P. L., Bates, S., and Pfeifer, G. P. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet., 25: 315-319, 2000.
13. Burbee, D. G., Forgacs, E., Zochbauer-Muller, S., Shivakumar, L., Fong, K., Gao, B., Randle, D., Kondo, M., Virmani, A., Bader, S., Sekido, Y., Latif, F., Milchgrub, S., Toyooka, S., Gazdar, A. F., Lerman, M. I., Zabarovsky, E., White, M., and Minna, J. D. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J. Natl. Cancer Inst. (Bethesda), 93: 691-699, 2001.
14. Schagdarsurengin, U., Gimm, O., Hoang-Vu, C., Dralle, H., Pfeifer, G. P., and Dammann, R. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res., 62: 3698-3701, 2002.
15. Lerman, M. I., and Minna, J. D. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res., 60: 6116-6133, 2000.
16. Dammann, R., Yang, G., and Pfeifer, G. P. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res., 61: 3105-3109, 2001.
17. Agathanggelou, A., Honorio, S., Macartney, D. P., Martinez, A., Dallol, A., Rader, J., Fullwood, P., Chauhan, A., Walker, R., Shaw, J. A., Hosoe, S., Lerman, M. I., Minna, J. D., Maher, E. R., and Latif, F. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene, 20: 1509-1518, 2001.
18. Nawroz, H., Koch, W., Anker, P., Stroun, M., and Sidransky, D. Microsatellite alterations in serum DNA of head and neck cancer patients. Nat. Med., 2: 1035-1037, 1996.
19. Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA, 93: 9821-9826, 1996.
20. Jeronimo, C., Usadel, H., Henrique, R., Oliveira, J., Lopes, C., Nelson, W. G., and Sidransky, D. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl. Cancer Inst. (Bethesda), 93: 1747-1752, 2001.
21. Lehmann, U., Langer, F., Feist, H., Glockner, S., Hasemeier B., and Kreipe, H. Quantitative assessment of promoter hypermethylation during breast cancer development. Am. J. Pathol., 160: 605-612, 2002.
22. Monney, L., Sabatos, C. A., Gaglia, J. L., Ryu, A., Waldner, H., Chernova, T., Manning, S., Greenfield, E. A., Coyle, A. J., Sobel, R. A., Freeman, G. J., and Kuchroo, V. K. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature (Lond.), 415: 536-541, 2002.
23. Kuzmin, I., Gillespie, J. W., Protopopov, A., Geil, L., Dreijerink, K., Yang, Y., Vocke, C. D., Duh, F. M., Zabarovsky, E., Minna, J. D., Rhim, J. S., Emmert-Buck, M. R., Linehan, W. M., and Lerman, M. I. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res., 62: 3498-3502, 2002.
24. Lee, M. G., Kim, H. Y., Byun, D. S., Lee, S. J., Lee, C. H., Kim, J. I., Chang, S. G., and Chi, S. G. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma. Cancer Res., 61: 6688-6692, 2001.
25. Shivakumar, L., Minna, J., Sakamaki, T., Pestell, R., and White, M. A. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol. Cell. Biol., 22: 4309-4318, 2002.
26. Dong, M. S., Sun, D. I., Benoit, E. N., Lerman, I. M., and Sidransky, D. Epigenic inactivation of RASSF1A in head and neck cancer. Clin. Cancer Res., in press.